California is set to become the first state to sell its own low-cost insulin, loosening Big Pharma’s grip on the market for the expensive diabetes drug and notching a win for Gov. Gavin Newsom’s CalRx program.
Through an agreement secured by nonprofit generic drug manufacturer Civica Rx with Biocon Biologics, California residents will be able to purchase an interchangeable biosimilar glargine insulin pen under the CalRx brand at a significantly reduced cost compared to other long-acting insulin brands.
The CalRx insulin pens, which people with the metabolic disease diabetes use to control blood sugar levels, will be available to consumers for a suggested retail price of no more than $55 per five-pack of pens beginning Jan. 1, according to a release from Newsom’s office.
Read more at Newsmax© 2025 Newsmax. All rights reserved.
